Trials / Completed
CompletedNCT02998671
Study of Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne
A Randomized, Subject and Investigator Blinded, Placebo-controlled, Multi-center Study in Parallel Groups to Assess the Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
The study was designed primarily to assess preliminary efficacy and safety of CJM112 in patients with moderate to severe inflammatory acne and to determine if CJM112 has an adequate clinical profile for further clinical development. In addition, sustainability of response and dose relationship were to be explored.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CJM112 | |
| OTHER | Placebo |
Timeline
- Start date
- 2016-12-22
- Primary completion
- 2018-08-01
- Completion
- 2018-08-01
- First posted
- 2016-12-20
- Last updated
- 2022-07-12
- Results posted
- 2019-10-10
Locations
10 sites across 3 countries: United States, Germany, Netherlands
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02998671. Inclusion in this directory is not an endorsement.